bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies
Authors: Vincent-Salomon A , Ferrari A , Pivot X , Macgrogan G , Arnould L , Treilleux I , Romieux G , Sertier A-S , Thomas E , Tonon L , Boyault S , Kielbassa J , Letexier V , Pauporte I , Birbaum D , Saintigny P , Cox D , Viari A 
Published: May 2016

Abstract
Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment.
Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098).
Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification.
Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants.
Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Abstract P6-08-08: Expression and role of ING3 gene in breast cancer
Authors: Kalender ME , Cakir M , Ergun S , Oztuzcu S , Cengiz B , Ulasli M , Sevinc A , Camci C 
Published: May 2016

Abstract
Background: Inhibitor of growth (ING) tumor suppressor gene family has been discovered over the past decade and five different genes have been identified from ING1 to ING5. They have some functions like cell transcription regulation, cell cycle control, DNA repair and apoptosis. Because of the fact that ING3 gene expression has not been studied in breast cancer so far, we aimed to determine whether there was a relationship between ING3 gene expression and breast cancer prognostic factors.
Methods: 46 female breast cancer patients in different stages were enrolled to our study. ING3 gene expressions obtained from tumoral and healthy breast tissue samples of patients were evaluated together with pathological and histological parameters.
Results: The median age of the patients was 49 years. ING3 expression rate has been significantly higher in the tumor tissue compared to normal tissue and was statistically significant (p=0.001). In estrogen receptor (ER) and progesterone receptor (PR) positive patients, gene expression ratio was significantly higher than negative ones (p&lt;0.001 and p&lt;0.001, respectively). ING3 expression in tumor tissues of the patients with advanced disease (stage 3-4) was detected higher than ones with early stage disease and it was found to be statistically significant at the border (p=0.048). Moreover, there were no significant changes when ING3 gene expressions were compared with c-erbB2 (Receptor tyrosine-protein kinase erbB-2) status and tumor grade (p&gt; 0.05).
Conclusions: This study was the first study on ING3 gene expression in breast cancer. ING3 gene expression has been shown to be associated with the receptor positivity and advanced stage disease. Further studies should be conducted on the prognostic significance of ING3 gene in breast cancer.
Citation Format: Kalender ME, Cakir M, Ergun S, Oztuzcu S, Cengiz B, Ulasli M, Sevinc A, Camci C. Expression and role of ING3 gene in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-08-08.
Abstract P6-12-02: Association between a dedicated program for young breast cancer patients and discussion about fertility preservation
Authors: Srikanthan A , Amir E , Warner E 
Published: May 2016

Abstract
Purpose: To assess whether a dedicated program, including a nurse navigator, improves the frequency of: a) documentation of fertility discussion and b) referrals for fertility preservation (FP).
Methods: A retrospective chart review and prospective survey were undertaken of a cohort of young breast cancer patients diagnosed between 2011-2013 at two academic centres in Toronto, Ontario. The Odette Cancer Center (OCC) has a dedicated program for young breast cancer patients while Princess Margaret Cancer Centre (PM) does not. Documentation of fertility discussion prior to receipt of systemic therapy was extracted from patient records. Prospective surveys were administered to the same cohort to corroborate data collected. Descriptive statistics were used to characterize baseline patient variables. Chi-squared was used to compare categorical variables and t-tests for continuous variables between the two cancer centres. Statistical significance was defined as p&lt;0.05.
Results: At OCC and PM respectively, 91 and 81 patient charts were reviewed while 54 and 49 women returned surveys for response rates of 59% and 60% . Chart reviews demonstrated no difference in the frequency of documentation of fertility discussion (80% versus 75% for OCC and PM, p=0.44); however, surveys demonstrated higher recall of fertility discussion rates at OCC (96% versus 83%, p=0.046). A greater proportion of women were offered FP referrals at OCC, as observed in both chart reviews (53% versus 41%, p=0.18) and surveys (70% versus 46%, p=0.02). Time to initiation of chemotherapy did not significantly differ between women who underwent FP and those who did not.
Conclusion: A dedicated program for young women with breast cancer including a nurse navigator is associated with a higher frequency of FP referrals without delaying systemic therapy.
Citation Format: Srikanthan A, Amir E, Warner E. Association between a dedicated program for young breast cancer patients and discussion about fertility preservation. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-12-02.
Abstract P6-12-07: The benefit of preoperative chemotherapy in an underinsured Hispanic population with poor use of screening mammography
Authors: Komenaka IK , Djenic B , Walters J , Hsu C-H , Nodora JN , Martinez ME , Bouton M , Mehta D 
Published: May 2016

Abstract
Background: Despite prospective clinical trials demonstrating the safety and effectiveness of preoperative chemotherapy for nearly 2 decades, it may still be underutilized in underserved, uninsured populations most likely to present with advanced cancers. The current study was performed to evaluate the effect of preoperative chemotherapy (PC) in a Hispanic safety net population.
Methods: A retrospective review of Hispanic breast cancer patients who presented at clinical stage 2 or higher and were treated from July 2001 to February May 2015 at a safety net hospital. Sociodemographic, clinical, and treatment variables were evaluated. Surgical outcomes were evaluated. Margin status was determined for those who underwent breast conservation.
Results: The average age of the 266 patients was 45 years. 93% of the patients were insured with Medicaid or uninsured (70%). Only 24% of patients underwent screening mammography. 133 underwent PC and 133 had primary operations. Patients who underwent PC presented with larger cancers (5cm vs 3.5cm, p &lt; 0.001). 96% of patients in PC group were not candidates for lumpectomy at presentation. However, lumpectomy was performed more often in those who underwent PC (75% vs. 57%, p = 0.01). Re-excision for margins were necessary less often in those who underwent PC (10.3% vs 27%, p = 0.01). Patients who underwent PC were also less likely to require an ALND (33% vs 47%, p = 0.04). Despite presentation at higher average clinical stage in patients who underwent PC, at average follow up of 52 months, risk of IBTR and risk of regional recurrence were similar in the PC and no-PC groups (IBTR: 4.4% vs 3%, p = 0.99 and Regional: 1.5% vs. 1.5%, p = 0.99). Breast cancer specific survival was 86.5% in the PC group compared to 84% in the no-PC group (p = 0.68). Patients in the no-PC group were less likely to comply with recommended chemotherapy.Conclusions: In this underinsured, Hispanic population who did not use screening mammography, preoperative chemotherapy allowed many women to undergo breast conservation, undergo fewer operations, and were less likely to require ALND. Risk of local and regional recurrence is low in these patients and comparable to those who underwent primary operation.
Citation Format: Komenaka IK, Djenic B, Walters J, Hsu C-H, Nodora JN, Martinez ME, Bouton M, Mehta D. The benefit of preoperative chemotherapy in an underinsured Hispanic population with poor use of screening mammography. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-12-07.
Abstract P6-13-14: Temporospatial delivery of chemotherapeutics from nanoparticles for synergy enhancement
Authors: Segura-Ibarra V , Wu S , Cara FE , Meric-Bernstam F , Ferrari M , Blanco E 
Published: May 2016

Abstract
INTRODUCTION
Chemotherapeutic synergy enhancement can be obtained when drugs are delivered in a sequential manner. However, clinical translation of synergistic combinations is not feasible due to different pharmacokinetic properties arising from distinct drug formulations that negate proper sequential delivery. Our laboratory has developed a platform for temporospatial delivery of agents in a sequential fashion for purposes of enhancing site-specific synergy. The system comprises a drug-containing poly(lactic-co-glycolic acid) (PLGA) core and an outer shell of drug complexed with β-cyclodextrin (β-CD). In this study, we demonstrate the therapeutic potential of this nanoparticle system by encapsulating two drugs, rapamycin (RAP) and paclitaxel (PTX). This combination has been shown to result in cell-killing synergy enhancement in when administered sequentially, and in a time staggered manner, in triple negative breast cancer (TNBC) in in vitro cell-based models.
EXPERIMENTAL METHODS
The final platform was fabricated by resuspending PLGA-PTX nanoparticles in an aqueous solution of RAP cyclodextrin complexes (RAP-CD) under sonication. Nanoparticles were characterized for size and surface charge. Drug concentration and release kinetics were determined by HPLC. In vitro growth inhibition in SUM159 TNBC cells was determined via MTT assay. Western blotting was used to confirm target knockdown. For in vivo efficacy analysis, SUM159 breast cancer cells (3×106) were inoculated in the mammary fat pads of 4- to 6-week–old female nu/nu mice, and treatments were administered intravenously once a week for a duration of 21 days.
RESULTS AND DISCUSSION
Nanoparticles had a mean diameter of 140 nm and zeta potential of -30 mV. After complexation with RAP-CD, the surface charge became 25 mV. Release kinetics depicted a fast release of RAP at early timepoints, while PTX showed a prolonged release. Nanoparticles showed concentration dependent cell-killing efficacy in SUM159 breast cancer cells in vitro, with knockdown of pS6, characteristic of RAP treatment, observed. Upon administration of NNPs to murine models of TNBC, NNPs showed significant tumor growth inhibition compared to controls, and knockdown of pS6.
CONCLUSION
We have developed a novel nanoparticle for the temporospatial release of drugs. The ability to localize agents site-specifically and deliver them sequentially should enable clinical translation of synergistic regimens observed in in vitro scenarios, in turn yielding more efficacious more efficacious outcomes following combination chemotherapy.
Citation Format: Segura-Ibarra V, Wu S, Cara FE, Meric-Bernstam F, Ferrari M, Blanco E. Temporospatial delivery of chemotherapeutics from nanoparticles for synergy enhancement. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-14.
Abstract A04: Differential DNA methylation and network analysis in African American breast cancer
Authors: Yu Kaixian , Steppi Albert , Xu Yun , Tang Ke , Zhang Jinfeng 
Published: May 2016

Abstract
African Americans (AAs) have more severe breast cancer, and higher death rate from breast cancer, than that of Caucasian Americans (CAs) even after socioeconomic status are accounted for. Various studies have been done to understand the biological mechanism of this health disparity. In this study, we performed a genome-wide differential DNA methylation analysis between AA and CA breast cancer patients. We analyzed differentially methylated positions (DMPs) and differentially methylated regions (DMRs) using data from 143 AA and 554 CA breast tumor tissues available at the Cancer Genome Atlas (TCGA). We found that there were 1232 DMPs and 661 DMRs between AA and CA breast cancer patients. Both DMP and DMR showed that PACS2 and ATP1A4 were highly differentially methylated among other genes. Network analysis showed that differential methylation occurred significantly in p53, EGFR, and ERS1 subnetwork, which is consistent from an early study on differentially expressed transcripts. We also conducted a correlation analysis between gene expression by RNA sequencing and DNA methylation, which showed that expressions of 129 genes with either DMP or DMR were highly negatively correlated with the corresponding DNA methylations, suggesting that these DNA methylation may play important roles in the breast cancer health disparity observed in AA women. Our discoveries may help researchers to better understand the biological factors for breast cancer health disparity and the biology of breast cancer in general. The genes or DMPs/DMRs identified may serve as the starting points for further experimental validations towards discovering biomarkers for cancer diagnosis and prognosis, and drug targets for personalized treatments.
Citation Format: Kaixian Yu, Albert Steppi, Yun Xu, Ke Tang, Jinfeng Zhang. Differential DNA methylation and network analysis in African American breast cancer. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr A04.
Abstract A10: Facebook advertisement effects on conversions and enrollment to a SMS/text smoking cessation service for young adult Latinos
Authors: Chalela Patricia , McAlister Alfred L. , Gallion Kipling J. , Muñoz Edgar , Despres Cliff , Akopian David , Perez Arely , Garcia Robert , Ramirez Amelie G. 
Published: May 2016

Abstract
Evidence shows that variations in the degree and type of a message's emotional arousal, particularly disgust, can influence message impact on smokers' interest in quitting and likelihood of seeking help. Negative emotional appeals are widely used to attract attention of Latino audiences, but positive appeals, especially those designed to increase smokers' confidence in their ability to quit, are also recommended as a way to attract them to enroll in cessation services.
Methods: We employed positive and negative variations in Facebook advertising appeals to study their effects on “conversions” and subsequent enrollment in a tobacco cessation service (a bilingual text messaging and mobile media service specifically targeting Latino young adults in South Texas). Differences in advertisement characteristics on conversion rate and enrollment were examined using exact Chi-squared tests for proportions and 95% confidence intervals for their corresponding odds ratios.
Results: The negative advertisement received a higher conversion rate than the positive ad, with 1,441/130,000 (1.11%) vs. 1,249/130,000 (1.96%) clicking the ad to visit our service's home page (OR= 1.16, 95% CI 1.07, 1.25). But subsequent texted enrollments in the cessation service were received by 76/1,249 (5.76%) of those exposed to the positive message and 55/1,441 (3.82%) of those exposed to the negative message (OR= 1.54, CI1.06, 2.25). The former were 54% more likely than the latter to become enrolled.
Conclusion: Negative-appealing advertising attracted more clicks to further information, but positive appeals were more likely to lead to subsequent enrollment. Negative advertising can gain attention and spark minor actions toward behavior change, but positive advertising appealing to the consumer's self-confidence is more likely to lead to an actual first step toward behavior change.
Citation Format: Patricia Chalela, Alfred L. McAlister, Kipling J. Gallion, Edgar Muñoz, Cliff Despres, David Akopian, Arely Perez, Robert Garcia, Amelie G. Ramirez. Facebook advertisement effects on conversions and enrollment to a SMS/text smoking cessation service for young adult Latinos. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr A10.
Abstract A39: Profiles, motivations, and networks of prostate cancer advocates in southern black communities
Authors: Gilbert Lauren Rose 
Published: May 2016

Abstract
Black men have the highest number of new cases and mortality rates for prostate cancer: 1.6 and 2.4, respectively when compared to whites (NCI, 2015). Also, black men are more likely to have an advanced stage and grade of prostate cancer at initial presentation. Prostate cancer disparities are a complex problem that needs to be assuaged with complex and multifaceted strategies. Advocates can be one of the many tools used to alleviate the prostate cancer health disparities that are observed today in black communities. While there is no shortage of research being done on black men and prostate cancer, there is a very little research on the work of advocates for prostate cancer awareness in black communities. Advocates are already engaging on different levels with black communities to increase prostate cancer awareness.
This research seeks to further illuminate the advocates' efforts and voices, exploring their strategies and approaches. Through the use of qualitative methods, data collection yielded a total of 24 in-depth interviews and 14 ethnographic observations. These expanded methods capture a more nuanced and complex understanding of prostate cancer advocacy. Major findings include (1) the description of the advocates, including their demographics and self-definitions, (2) the interrelated internal and external sources of motivation for their advocacy efforts; and (3) an examination of the complex networks of advocacy that incorporate social networks, organizations, and research and political entities. These insights can help to create and support more effective interventions that are specifically developed for men in black communities.
Citation Format: Lauren Rose Gilbert. Profiles, motivations, and networks of prostate cancer advocates in southern black communities. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr A39.
Abstract B03: PVT1 exon 9 is a potential non-invasive biomarker that regulates apoptosis and the cell cycle in aggressive prostate cancer in black males
Authors: Ilboudo Adeodat , Das Dibash , Ogunwobi Olorunseun O. 
Published: May 2016

Abstract
Prostate cancer (PCA) is the most common non-skin cancer and the second leading cause of cancer-related death for men in the U.S. Black males have a higher incidence of PCA, compared to White males. In fact, Black race is a confirmed, non-modifiable risk factor for PCA with a 2.5 fold greater risk of lethal PCA compared to Caucasian males. Discovery of effective early detection strategies are necessary to address the profound health disparity. The chromosomal region 8q24 is associated with aggressive PCA in Black men and variants of this region have been identified to interact with the PVT1 non-protein coding gene in PCA. PVT1 is located at 8q24 and is transcribed into a long non-protein coding RNA that has been implicated in PCA. Using a panel of eight prostate epithelial cell lines modeling a variety of clinical characteristics of PCA, we investigated the expression of 12 exons of PVT1 in PCA. We discovered that exon 9 of PVT1 is consistently significantly upregulated (by about 2-folds) in aggressive PCA cell lines derived from Black males (MDA PCa 2b and E006AA-hT) in comparison to indolent PCA cells from a Black male E006AA, and both indolent and aggressive PCA cell lines derived from White males. Cell-free PVT1 exon 9 was detectable in cell culture medium, and found to be detectable at significantly higher levels from the aggressive E006AA-hT cell line in comparison to the indolent E006AA cell line from which it was derived. PVT1 exon 9 was efficiently silenced by a custom-designed siRNA. We observed that silencing of PVT1 exon 9 expression resulted in apoptosis and cell cycle arrest at G1 phase in the MDA PCa 2b cell line derived from a Black male. Consequently, PVT1 exon 9 may regulate apoptosis and the cell cycle in aggressive PCA in Black males. Our ability to detect cell-free PVT1 exon 9 indicates that PVT1 exon 9 may have potential future role in non-invasive early detection of aggressive PCA in Black males.
Citation Format: Adeodat Ilboudo, Dibash Das, Olorunseun O. Ogunwobi. PVT1 exon 9 is a potential non-invasive biomarker that regulates apoptosis and the cell cycle in aggressive prostate cancer in black males. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr B03.